Does the media prefer DYN or ASND?

In the previous week, Dyne Therapeutics had 20 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 34 mentions for Dyne Therapeutics and 14 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.83 beat Dyne Therapeutics' score of 0.44 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Ascendis Pharma A/S 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DYN or BBIO?

In the previous week, Dyne Therapeutics had 10 more articles in the media than BridgeBio Pharma. MarketBeat recorded 34 mentions for Dyne Therapeutics and 24 mentions for BridgeBio Pharma. Dyne Therapeutics' average media sentiment score of 0.44 beat BridgeBio Pharma's score of 0.34 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral BridgeBio Pharma 8 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is EXEL or DYN more profitable?

Exelixis has a net margin of 35.33% compared to Dyne Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Dyne Therapeutics N/A -64.30% -50.33%

Does the media prefer EXEL or DYN?

In the previous week, Dyne Therapeutics had 11 more articles in the media than Exelixis. MarketBeat recorded 34 mentions for Dyne Therapeutics and 23 mentions for Exelixis. Exelixis' average media sentiment score of 1.07 beat Dyne Therapeutics' score of 0.44 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 11 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor BMRN or DYN?

In the previous week, Dyne Therapeutics had 17 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 34 mentions for Dyne Therapeutics and 17 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.68 beat Dyne Therapeutics' score of 0.44 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor DYN or MDGL?

In the previous week, Dyne Therapeutics had 28 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 34 mentions for Dyne Therapeutics and 6 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.45 beat Dyne Therapeutics' score of 0.44 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Madrigal Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Dyne Therapeutics (DYN) Competitors

$18.42 -0.77 (-4.01%)

Closing price 09/10/2026 04:00 PM Eastern

Extended Trading

$18.70 +0.27 (+1.49%)

As of 06:07 AM Eastern

Compare

DYN vs. ASND, BBIO, EXEL, BMRN, and MDGL

Should you buy Dyne Therapeutics stock or one of its competitors? Dyne Therapeutics's main competitors and comparable companies include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), and Madrigal Pharmaceuticals (MDGL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Dyne Therapeutics compare to Ascendis Pharma A/S?

Dyne Therapeutics (NASDAQ:DYN) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Dyne Therapeutics currently has a consensus target price of $32.17, suggesting a potential upside of 74.63%. Ascendis Pharma A/S has a consensus target price of $310.00, suggesting a potential upside of 18.67%. Given Dyne Therapeutics' higher possible upside, equities research analysts plainly believe Dyne Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.81
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.05

Ascendis Pharma A/S has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Ascendis Pharma A/S	$814.57M	20.01	-$258M	$12.89	20.27

In the previous week, Dyne Therapeutics had 20 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 34 mentions for Dyne Therapeutics and 14 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.83 beat Dyne Therapeutics' score of 0.44 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 70.99% compared to Dyne Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Dyne Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market.

96.7% of Dyne Therapeutics shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Ascendis Pharma A/S beats Dyne Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Dyne Therapeutics compare to BridgeBio Pharma?

Dyne Therapeutics (NASDAQ:DYN) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

Dyne Therapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

In the previous week, Dyne Therapeutics had 10 more articles in the media than BridgeBio Pharma. MarketBeat recorded 34 mentions for Dyne Therapeutics and 24 mentions for BridgeBio Pharma. Dyne Therapeutics' average media sentiment score of 0.44 beat BridgeBio Pharma's score of 0.34 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
BridgeBio Pharma	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyne Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
BridgeBio Pharma	-97.03%	N/A	-61.19%

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Dyne Therapeutics currently has a consensus price target of $32.17, suggesting a potential upside of 74.63%. BridgeBio Pharma has a consensus price target of $101.53, suggesting a potential upside of 40.04%. Given Dyne Therapeutics' higher possible upside, equities analysts clearly believe Dyne Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.81
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Dyne Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
BridgeBio Pharma	$502.08M	28.23	-$724.93M	-$3.57	N/A

Summary

Dyne Therapeutics beats BridgeBio Pharma on 10 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

Exelixis has a net margin of 35.33% compared to Dyne Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Dyne Therapeutics	N/A	-64.30%	-50.33%

Exelixis has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.13	$782.57M	$3.18	18.06
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

Exelixis has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

In the previous week, Dyne Therapeutics had 11 more articles in the media than Exelixis. MarketBeat recorded 34 mentions for Dyne Therapeutics and 23 mentions for Exelixis. Exelixis' average media sentiment score of 1.07 beat Dyne Therapeutics' score of 0.44 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	11 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Exelixis currently has a consensus target price of $50.07, indicating a potential downside of 12.82%. Dyne Therapeutics has a consensus target price of $32.17, indicating a potential upside of 74.63%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.81

Summary

Exelixis and Dyne Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

BioMarin Pharmaceutical has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

BioMarin Pharmaceutical has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	3.94	$348.90M	$0.37	177.05
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Dyne Therapeutics had 17 more articles in the media than BioMarin Pharmaceutical. MarketBeat recorded 34 mentions for Dyne Therapeutics and 17 mentions for BioMarin Pharmaceutical. BioMarin Pharmaceutical's average media sentiment score of 0.68 beat Dyne Therapeutics' score of 0.44 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

BioMarin Pharmaceutical presently has a consensus price target of $89.17, suggesting a potential upside of 36.12%. Dyne Therapeutics has a consensus price target of $32.17, suggesting a potential upside of 74.63%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than BioMarin Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	2.74
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.81

BioMarin Pharmaceutical has a net margin of 2.14% compared to Dyne Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Dyne Therapeutics	N/A	-64.30%	-50.33%

Summary

BioMarin Pharmaceutical beats Dyne Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Dyne Therapeutics compare to Madrigal Pharmaceuticals?

Dyne Therapeutics (NASDAQ:DYN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Dyne Therapeutics has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, indicating that its stock price is 198% less volatile than the broader market.

Dyne Therapeutics currently has a consensus price target of $32.17, indicating a potential upside of 74.63%. Madrigal Pharmaceuticals has a consensus price target of $699.64, indicating a potential upside of 31.24%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Dyne Therapeutics is more favorable than Madrigal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.81
Madrigal Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Dyne Therapeutics had 28 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 34 mentions for Dyne Therapeutics and 6 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 1.45 beat Dyne Therapeutics' score of 0.44 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral
Madrigal Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Madrigal Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
Madrigal Pharmaceuticals	$958.40M	12.85	-$288.28M	-$12.89	N/A

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dyne Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -25.32%. Madrigal Pharmaceuticals' return on equity of -56.65% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Madrigal Pharmaceuticals	-25.32%	-56.65%	-25.53%

Summary

Dyne Therapeutics and Madrigal Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Dyne Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYN vs. The Competition

Export

Metric	Dyne Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.58B	$3.89B	$7.21B	$12.81B
Dividend Yield	N/A	3.63%	2.56%	10.55%
P/E Ratio	-5.53	13.60	272.82	25.11
Price / Sales	N/A	1,333.40	620.94	90.53
Price / Cash	N/A	106.61	77.33	51.83
Price / Book	2.70	15.38	10.43	6.18
Net Income	-$446.21M	-$22.82M	$3.49B	$358.18M
7 Day Performance	-24.14%	-3.97%	-3.16%	-2.51%
1 Month Performance	-31.04%	0.27%	0.02%	-2.73%
1 Year Performance	39.76%	38.62%	17.34%	7.73%

Dyne Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYN Dyne Therapeutics	3.0879 of 5 stars	$18.42 -4.0%	$32.17 +74.6%	+38.7%	$3.58B	N/A	N/A	100	Trending News Analyst Forecast Insider Trade Options Volume
ASND Ascendis Pharma A/S	4.414 of 5 stars	$263.04 +6.1%	$304.95 +15.9%	+31.6%	$15.46B	$814.57M	20.41	1,189	Positive News Analyst Forecast Insider Trade High Trading Volume
BBIO BridgeBio Pharma	3.437 of 5 stars	$76.59 0.0%	$100.79 +31.6%	+36.9%	$14.97B	$502.08M	N/A	400	Trending News Analyst Forecast
EXEL Exelixis	2.5378 of 5 stars	$54.64 +0.3%	$50.07 -8.4%	+52.3%	$13.49B	$2.32B	17.18	1,077	Positive News
BMRN BioMarin Pharmaceutical	4.6951 of 5 stars	$65.23 +0.9%	$88.92 +36.3%	+20.2%	$12.52B	$3.22B	176.30	3,221	Trending News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYN) was last updated on 9/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyne Therapeutics (DYN) Competitors

DYN vs. ASND, BBIO, EXEL, BMRN, and MDGL

How does Dyne Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Dyne Therapeutics compare to BridgeBio Pharma?

Summary

How does Dyne Therapeutics compare to Exelixis?

Summary

How does Dyne Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Dyne Therapeutics compare to Madrigal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyne Therapeutics (DYN) Competitors

DYN vs. ASND, BBIO, EXEL, BMRN, and MDGL

How does Dyne Therapeutics compare to Ascendis Pharma A/S?

Do analysts rate DYN or ASND?

Which has stronger earnings & valuation, DYN or ASND?

Does the media prefer DYN or ASND?

Is DYN or ASND more profitable?

Which has more volatility and risk, DYN or ASND?

Do insiders & institutionals hold more shares of DYN or ASND?

Summary

How does Dyne Therapeutics compare to BridgeBio Pharma?

Which has more risk and volatility, DYN or BBIO?

Does the media refer more to DYN or BBIO?

Is DYN or BBIO more profitable?

Do insiders & institutionals have more ownership in DYN or BBIO?

Do analysts recommend DYN or BBIO?

Which has preferable valuation & earnings, DYN or BBIO?

Summary

How does Dyne Therapeutics compare to Exelixis?

Is EXEL or DYN more profitable?

Which has better earnings & valuation, EXEL or DYN?

Which has more volatility & risk, EXEL or DYN?

Does the media prefer EXEL or DYN?

Do institutionals & insiders believe in EXEL or DYN?

Do analysts recommend EXEL or DYN?

Summary

How does Dyne Therapeutics compare to BioMarin Pharmaceutical?

Which has more volatility & risk, BMRN or DYN?

Which has better valuation & earnings, BMRN or DYN?

Do insiders and institutionals have more ownership in BMRN or DYN?

Does the media favor BMRN or DYN?

Do analysts rate BMRN or DYN?

Is BMRN or DYN more profitable?

Summary

How does Dyne Therapeutics compare to Madrigal Pharmaceuticals?

Which has more risk and volatility, DYN or MDGL?

Do analysts recommend DYN or MDGL?

Does the media favor DYN or MDGL?

Which has better valuation and earnings, DYN or MDGL?

Do insiders & institutionals believe in DYN or MDGL?

Is DYN or MDGL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools